Hong Kong, 26 April 2013--The leading healthcare company in China, Shanghai Fosun Pharma(Group)Ltd. (「Fosun Pharma」or「Company」；ticker：600196-SH，02196-HK，and its subsidiaries 「Group」) announced today that Fosun Pharma will invest up to 240 million USD jointly with Pramerica-Fosun China Opportunity Fund, L.P. to acquire up to 95.6% share of Israel-based Alma Lasers Ltd. 

Through this transaction, Fosun Pharma will achieve an important milestone in its strategy of growing its global business. After its IPO on the H share market in Hong Kong in 2012 and gaining access to the international capital markets, Fosun Pharma will now complete its first international healthcare acquisition project. The medical devices business of Fosun Pharma will continue its strategy of moving from product distribution to R&D and manufacturing, and gain a leading position in the international aesthetic medical device market segment. 

Alma Lasers is a leading global medical and cosmetic energy-based (including lights, laser, radio frequency and ultrasound) device manufacturer, with a comprehensive product offering and international sales network. Alma Lasers has developed world-class R & D capabilities in the medical and cosmetic energy-based device manufacturing field and established a global leading brand in the market segment. Alma Lasers has an outstanding track record of maintaining sustainable and rapid growth. In the past decade, Alma Lasers has delivered strong performance. In 2012, Alma Lasers recorded nearly USD $100 million total revenue. According to independent third-party research, Alma has an overall 15% market share in the global high-end aesthetic energy-based device segment. 

The medical and cosmetic energy-based device industry is composed of 3 sub-segments: Aesthetic energy-based devices, Surgical energy-based devices and the Home-Use energy-based devices. Alma Lasers is one of the market leaders in the Aesthetic energy-based device market, and entered the surgical energy-based device market in late 2012. It has completed initial research and development in the Home-Use energy-based device segment as well. 

Commenting on Fosun Pharma’s acquisition, Alma Laser’s CEO Ziv Karni said, "The Alma Lasers team is delighted to be joining Fosun. Fosun's successful international M&A experience and strategic focus on healthcare and aesthetic and medical devices provide Alma Lasers with an exceptional platform to grow our business in Asia and globally. We look forward to working with the management team of Fosun and benefiting from their expertise.”

The global medical and cosmetic energy-based device sector exhibits strong growth potential. Alma Lasers entered the China market in 2003 and rapidly became the market leader in the high-end market segment for energy-based aesthetic medical device. At present, China is one of the largest markets in the world for Alma.

Qiyu Chen, Chairman of Fosun Pharma, said "We are very optimistic about the growth prospects of the global medical and cosmetic energy-based device market, especially in the Brazil, Russia, India and China, as well as other emerging markets. Fosun Pharma will continue to support Alma’s global expansion. Fosun Pharma will build on Alma’s strength and be committed to developing a high-end medical device research, manufacturing platform. The acquisition demonstrates Fosun Pharma’s strategy in pursuit of global expansion.” 

Background Info:
Alma Lasers

Established in 1999, Alma Lasers is a leading global medical and cosmetic energy-based (including lights, laser, radio frequency and ultrasound) device manufacturer, with a comprehensive product offering and international sales network. Its global headquarters is located in the high tech park of Caesarea, Israel, with North America sales and supporting center in Chicago, Illinois. 2012, Alma Lasers recorded close to USD $100 million total revenue. According to Independent research, Alma has occupied 15% market share in the global high-end aesthetic energy-based device segment. Alma Lasers entered China market in 2003 and has become the market leader of the high end aesthetic energy-based devices.

The leading R&D and technical strength of Alma

The founder of Alma Dr. Ziv Karni, currently serves as CEO of the company. He, as the holder of tens of patents in medical laser technology sector, has more than 20 years’ experience in the research and development of medical laser. Dr. Ziv Karni is one of the pioneers who bring the medical laser technology into the medical aesthetic industry; he currently focuses on the combination of laser technology with clinical application. By the end of 2012, the R&D team with around 40 people led by him has developed and registered 74 patents, another 23 applications are being processed.